No, you do not need to stop celecoxib (Celebrex) when starting prednisone in juvenile reactive arthritis
NSAIDs like celecoxib are conditionally recommended as adjunct therapy and can be continued alongside glucocorticoids in children with juvenile arthritis. 1
Rationale for Continuing Both Medications
The 2019 ACR/Arthritis Foundation guidelines for juvenile idiopathic arthritis explicitly support the concurrent use of NSAIDs with glucocorticoids:
- NSAIDs serve as adjunct therapy for symptom management, particularly during initiation or escalation of other therapies 1
- Bridging glucocorticoids (short courses <3 months) are conditionally recommended during treatment initiation or escalation, and this recommendation does not require NSAID discontinuation 1
- The guidelines specifically address enthesitis and sacroiliitis (conditions closely related to reactive arthritis), recommending NSAIDs as first-line with bridging glucocorticoids added when needed 1
Clinical Considerations
For juvenile reactive arthritis specifically:
- NSAIDs remain the foundation of symptomatic treatment 1
- Prednisone serves as bridging therapy to rapidly control high disease activity, limited mobility, or significant symptoms 1
- Both medications work through different mechanisms and provide complementary benefits
Important caveats:
- The prednisone course should be limited to <3 months 1
- Monitor for gastrointestinal side effects, as both drug classes can affect the GI tract, though celecoxib has a more favorable GI profile than non-selective NSAIDs 2, 3
- One older study 4 showed prednisone increased salicylate clearance in JRA, but this interaction is not clinically significant with celecoxib and does not warrant discontinuation
The goal is rapid disease control while the prednisone takes effect, then taper and discontinue the glucocorticoid within 3 months while maintaining the NSAID for ongoing symptom management 1.